ospemifene


( Last Updated : September 21, 2021)
Generic Name:
ospemifene
Project Status:
Pending
Therapeutic Area:
Dyspareunia, vaginal dryness
Manufacturer:
Duchesnay Inc.
Call for patient/clinician input open:
Brand Name:
Osphena
Project Line:
Reimbursement Review
Project Number:
SR0709-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
‚ÄčOsphena is indicated in postmenopausal women for the treatment of moderate to severe dyspareunia and/or vaginal dryness, symptoms of vulvar and vaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM).
Fee Schedule:
Pending
Indications:
Osphena is indicated in postmenopausal women for the treatment of moderate to severe dyspareunia and/or vaginal dryness, symptoms of vulvar and vaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.